Market Intelligence, Preclinical Progress, and High-Purity Reagents for Chronic Kidney Disease, Metabolic Disease, and Cancer Metabolism Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NAT8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Wild-Type Enzyme | NAT8 Full-Length Recombinant Protein (His/HEK293). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. | View NAT8 Products |
| Mutant Panel | NAT8 Active Site Mutant Proteins (e.g., Cys→Ser). Catalytic dead negative control for enzyme assays. HEK293 expressed. | View NAT8 Products |
| Ortholog Panel | Human/Mouse/Rat NAT8 Protein Set. For cross-species pharmacokinetic validation. >95% purity. | View NAT8 Products |
| Antigen | NAT8 Recombinant Protein (Full-Length / Catalytic Domain). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. | View NAT8 Products |
| Gene Delivery | NAT8 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines in metabolic flux and mitochondrial localization assays. | View NAT8 Products |
| Benchmark Ab | Anti-NAT8 Antibody. Recombinant positive control. Sequence Verified. For Western blot and ELISA. | View NAT8 Products |
| Validator | NAT8 siRNA Set. For knockdown and specificity verification in rescue experiments. | View NAT8 Products |
| Activity Validator | NAT8 Substrate (Taurine Analog). Reference compound for acetyltransferase assays. | View NAT8 Products |
| Selectivity Counterscreen A | NAT1 Recombinant Protein. Isoform for off-target liability screening. >95% purity, Mass Spec verified. | View NAT1 Products |
| Selectivity Counterscreen B | NAT2 Recombinant Protein. Isoform for toxicology profiling. >95% purity. | View NAT2 Products |
| Related Target A | NAT8L (NAT8B). Homolog for CNS side-effect assessment. | View NAT8L Products |
| Related Target B | NAA40. GNAT superfamily off-target liability panel member. | View NAA40 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (NAT8 vs NAT1/NAT2 share >60% homology) | Homolog Panel proteins (NAT1, NAT2, NAT8L, NAA40) strictly verified by Mass Spec; available for parallel SPR or Thermal Shift screening. |
| Poor solubility/misfolding in bacterial systems | HEK293 Expressed mammalian proteins ensuring native folding and solubility for enzymatic assays. |
| Need for catalytically dead negative controls | Mutant panel (active site variants) with Sequence Verified identity and Theoretical MW confirmed. |
| Enzymatic Activity Standardization | Acetyl-CoA Consumption Assay validated; Catalytic Dead Mutant included as negative control. |
| Mitochondrial Localization Studies | Full-length ORF Lentivirus particles for stable cell line generation; HEK293 expressed native proteins with MTS. |
| Cross-species Translation (Mouse to Human) | Human/Mouse/Rat ortholog proteins available with matched purity specifications (>95%). |
| Lack of knockdown validation standards | Predesigned siRNA included for specificity checks in rescue experiments. |
Live NAT8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Latest Metabolic Research
- ➤ Cancer Metabolism Mechanism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for NAT8-targeted therapeutics is concentrating in early-stage discovery, with major academic and biotech players shifting focus toward Chronic Kidney Disease (CKD), metabolic syndrome, and cancer metabolism. NAT8 (N-acetyltransferase 8), a mitochondrial enzyme in the mercapturic acid pathway, is emerging as a target for nephrotoxicity regulation, blood pressure control, and ferroptosis modulation. The next wave of R&D is targeting selective small molecule inhibitors, RNA interference (RNAi), PROTAC degraders, and allosteric modulators to precisely modulate renal acetylation, mitochondrial metabolism, and tumor microenvironment. Key challenges include isoform selectivity (vs NAT1/NAT2), mitochondrial localization validation, and cross-species translation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Consortia, Early Biotech | CKD, Metabolic Syndrome, Solid Tumors | Isoform Selectivity Assay (Need Homolog Panel >95% purity) |
| RNAi / siRNA | Preclinical Innovators, Functional Genomics | Nephrotoxicity, Pathway Deconvolution | Knockdown Validation (Need Sequence-Verified siRNA & ORF lentivirus) |
| Monoclonal Ab | Diagnostic Developers | Biomarker Detection | Binding Assays (Need HEK293 Expressed NAT8) |
| PROTAC Degrader | Preclinical Programs | Solid Tumors (Metabolic Reprogramming) | Intracellular Target Engagement (Need Full-length NAT8 Lentivirus) |
| Allosteric Modulator | Discovery Stage | Neurodegeneration, NASH | Thermal Shift Assay (Need High-concentration Stable Proteins, Endotoxin <1EU/µg) |
(Note: Competitive landscape is derived from multiple candidate contributions, deduplicated and consolidated.)